The device is being designed specifically for several low-resource areas outside the U.S., Masimo said. The company will be developing the device to measure both oxygen saturation and respiration rate, which it says provide helpful additional information in pneumonia screenings.
“We are excited to partner with Masimo for the purpose of improving screening for pneumonia to allow improved referral decisions by health workers in low-resource settings. Evaluating a child for fast breathing is the cornerstone of pneumonia assessment and combining this with a reliable and effective approach to assessing oxygen saturation can have significant impact in ensuring children with pneumonia receive appropriate care. Our landscape review of pneumonia diagnostic aid technologies has clearly demonstrated the poor performance of existing diagnostic aids, particularly respiratory rate timers. Diagnostic aids with improved sensitivity and specificity that are adapted and designed for use by health workers and caregivers can make a significant impact on pneumonia treatment. We look forward to working with Masimo to adapt their precise and accurate technology to respond to the needs of health workers, caregivers, and children in countries where pneumonia burden and deaths remain unacceptably high,” BMGF pneumonia senior program officer Rasa Izadnegahdar said in a prepared statement.
Funds from the grant will also support the study of clinical use environments in such settings to create a device that is user friendly for its intended purpose. Extra funds form the grant may also support education and training on the device at multiple literacy levels.
“We are gratified to be able to partner with BMGF, which recently joined us in co-founding the United for Oxygen Alliance to increase access to oxygen and pulse oximetry in Ethiopia, in supporting our efforts to help fight pneumonia. We hope to bring a much-needed screening tool to areas of the world blighted by countless needless deaths that are due to an illness considered low-risk in the developed world,” Masimo CEO Joe Kiani said in a prepared release.
Last week, Masimo said that Royal Philips (NYSE:PHG) agreed to pay $300 million to resolve all outstanding legal disputes between the companies, with both inking a multi-year patient monitoring partnership deal.
The dismissal includes a patent infringement and antitrust suit pending in the U.S. District Court for the District of Delaware, Masimo said. In the agreement, both parties agreed “not to sue each other for patent infringement for certain of each other’s products.”
The post Masimo lands $5m Gates Foundation grant appeared first on MassDevice.
from MassDevice http://ift.tt/2eznmNj
Cap comentari:
Publica un comentari a l'entrada